Back to announcement
20251223_OMED_Laporan Informasi dan Fakta Material_32014998_lamp3.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 2
Page 1
INFORMATION DISCLOSURE
REGARDING THE TERMINATION OF THE SHARE BUYBACK PROGRAM OF PT JAYAMAS
MEDICA INDUSTRI Tbk (the “Company”)
This disclosure is made in order to comply with Financial Services Authority (“OJK”) Regulation
Number 29 of 2023 concerning the Repurchase of Shares Issued by Public Companies.
PT JAYAMAS MEDICA INDUSTRI Tbk
Main Business Activities:
Engaged in the manufacture of medical devices, electromedical devices, diagnostic devices,
antiseptics and disinfectants, and other household medical supplies
Head Office:
By Pass Krian Ds. Sidomojo
Krian Sidoarjo, Jawa Timur 61262
Telp: (0231) 898 2349 / (0231) 898 5268
Website: http://onemed.co.id
Email Corporate Secretary: corporate.secretary@onemed.co.id
Email Investor Relation: ir@onemed.co.id
This Disclosure is important for the Company's Shareholders to read and pay attention to
regarding the Termination of the Share Buyback.
If you have difficulty understanding the information contained in this Disclosure, you should
consult with a legal advisor, public accountant, financial advisor, or other professional.
The Board of Commissioners and Board of Directors of the Company, both individually and
collectively, are fully responsible for the completeness and accuracy of all information or
material facts contained in this Disclosure and confirm that the information presented in this
Disclosure is true and that there are no undisclosed material facts that could cause the
material information in this Disclosure to be untrue and/or misleading.
This Disclosure of Information was published in Sidoarjo on December 23, 2025
Page 2
INFORMATION ON THE SUSPENSION OF THE SHARE BUYBACK PROGRAM
With reference to the information disclosure made by the Company on June 24, 2025, the
Company is currently in the process of repurchasing its shares in accordance with Article 9
Paragraph (1) of Financial Services Authority Regulation (“OJK”) Number 29 of 2023 concerning
the Repurchase of Shares Issued by Public Companies (“POJK 29/2023”) with a mandatory
share repurchase period of no later than 12 (twelve) months after the date of the GMS that
approved the share repurchase, namely in the period from June 27, 2025 to June 27, 2026.
At the Extraordinary General Meeting of Shareholders (“EGMS”) held on June 26, 2025, we
announced that the Company had obtained shareholder approval for the plan to repurchase
shares issued by the Company in accordance with POJK 29/2023.
In connection with the above, to comply with the provisions of Article 9 Paragraph (2) of POJK
29/2023, in the event that a Public Company intends to terminate the implementation of the
share buyback before the completion of the share buyback, the Company is required to
disclose and announce information to the public regarding the termination of the share
buyback, along with the reasons for the termination, no later than 2 (two) business days after
the decision to terminate the implementation of the share buyback.
Therefore, the Company has decided to terminate the Share Buyback Program, effective
December 11, 2025, based on Decree Number 0143/PR/DIR-JMI/XII/25 regarding the
Termination of the Share Buyback Program issued by the Company on December 20, 2025. The
termination of the Share Buyback Program is in line with the fulfillment of the limits agreed
upon at the Extraordinary General Meeting of Shareholders on June 26, 2025. Regarding the
Share Buyback, the Company has realized a total value of Rp4,876,241,168 for the repurchase
of 24,993,800 shares.
IMPACT OF EVENTS/INFORMATION ON THE CONTINUITY OF THE COMPANY'S BUSINESS
The termination of the Share Buyback period has no significant impact on the Company's
operational activities, legal status, financial condition, or business continuity
ADDITIONAL INFORMATION
To shareholders of the Company who require more detailed information regarding this
Disclosure, shareholders of the Company may submit their requests to the Corporate
Secretary and Investor Relations of the Company, on any business day and during business
hours of the Company at the address below:
Head Office:
By Pass Krian Ds. Sidomojo
Krian Sidoarjo, Jawa Timur 61262
Telp: (0231) 898 2349 / (0231) 898 5268
Website: http://onemed.co.id
Email Corporate Secretary: corporate.secretary@onemed.co.id
Email Investor Relation: ir@onemed.co.id
Names mentioned 2 people and organisations named in the text · linked when the evidence is strong
unresolved
org
Financial Services Authority
p.1 ×2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.